ArticleJournal of gastrointestinal oncology2023
Durable response to first-line PARP inhibition in
Article in Journal of gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer.Scientific reports · 2026Article
- Chromosomal instability and genomic alterations in cholangiocarcinoma from Northeastern Thailand.The Journal of pathology · 2025Article
- Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?International journal of cancer · 2025Article
- The efficacy of olaparib as salvage therapy in an advanced intrahepatic cholangiocarcinoma patient harboring somaticFrontiers in pharmacology · 2025Article
- A case report of advanced small intestinal stromal tumor with KIT gene mutation and BRCA2 deletion after multi-line treatments.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cholangiocarcinoma (CCA) is an increasingly prevalent malignancy worldwide, with poor outcomes even when diagnosed at an early stage. While recent trials have shown benefit from the addition of immunotherapy to standard-of-care chemotherapy, the improvement in overall survival is modest. Multiple novel therapies for advanced CCA targeting actionable genetic alterations have been approved in recent years; Case Description: We report the case of a 79-year-old man with metastatic extrahepatic CCA harboring a somatic Conclusions: This case adds to a growing list of retrospective studies supporting the clinical activity of PARP inhibitors in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.